疆煤外运领军企业，轻装上阵未来可期 买入 （首次） 当前价：6.75 元 [Table_StockInfo] 2026 年 02 月 10 日 证券研究报告•公司研究报告 广汇物流（600603）交通运输 目标价：8.40 元（6 个月） 风险提示：行业政策风险，业务经营风险，其他铁路线路竞争的风险等。 | [Table_MainProfit] 指标/年度 | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业收入（百万元） | 3737.11 | 3526.63 | 4053.29 | 4894.90 | | 增长率 | -24.23% | -5.63% | 14.93% | 20.76% | | 归属母公司净利润（百万元） | 508.90 | 411.37 | 720.56 | 1094.35 | | 增长率 | -12.76% | -19.16% | 75.16% | 51.87% | | 每股收益 EPS（元） | 0.43 | 0.34 | 0.60 | 0.92 | | 净资产收益率 ROE | 7.07% | ...

Investment Rating - The report maintains a rating of "Buy" for the company [4][8]. Core Insights - The company's consolidated revenue for January 2026 increased by 87.6% year-on-year, with a target price raised to 189.2 CNY, reflecting a 43x PE ratio for 2026 [4][6]. - The company is expanding its overseas market presence, particularly in Southeast Asia, and has established a wholly-owned subsidiary in Singapore [6][4]. - The financial forecasts indicate a projected EPS growth of 5.2%, 40.5%, and 20.2% for 2025, 2026, and 2027 respectively [4][7]. Financial Summary - The consolidated revenue for January 2026 was 6.56 billion NTD (approximately 1.44 billion CNY), with a 30.9% decrease month-on-month [4]. - The total revenue for Q4 2025 was 25.08 billion NTD (approximately 5.52 billion CNY), showing a year-on-year increase of 133.7% [4]. - The projected total revenue for 2025 is 76.74 billion NTD (approximately 16.90 billion CNY), reflecting an 18.1% increase [4][7]. - The net profit attributable to the parent company is expected to reach 940 million CNY in 2026, with a net profit margin of 14.7% [7][14]. Valuation Metrics - The current price is 143.78 CNY, with a target price of 189.20 CNY, indicating significant upside potential [8]. - The company has a current PE ratio of 31.8x for 2026, which is relatively high compared to its peers [6][16]. - The company's dividend yield is currently at 1.4%, with a proposed payout ratio of 33.6% for 2024 [6][7].

Investment Rating - The report assigns a "Buy" rating for Longxin General (隆鑫通用) as a first-time coverage [1] Core Views - Longxin General is a leading company in the motorcycle and all-terrain vehicle sectors in China, with a strategic focus on three main business areas: motorcycles, all-terrain vehicles, and general machinery. The company has made significant advancements in high-end motorcycle series and smart garden machinery through continuous technological innovation [2][4] - The collaboration with Zongshen Power, a major shareholder, is expected to enhance the company's core competitiveness through synergies in technology research and development, supply chain management, and overseas channels [2] - The company is projected to achieve net profits of 1.73 billion, 2.25 billion, and 2.70 billion yuan for the years 2025, 2026, and 2027, respectively, with corresponding EPS of 0.84, 1.10, and 1.31 yuan. The current stock price corresponds to PE ratios of 18.9, 14.5, and 12.1 times for the same years [2] Financial Summary and Valuation Indicators - Revenue is expected to grow from 13.066 billion yuan in 2023 to 27.396 billion yuan in 2027, with a CAGR of 12.7% from 2020 to 2024 [6][28] - The net profit attributable to shareholders is projected to increase from 583 million yuan in 2023 to 2.698 billion yuan in 2027, with a CAGR of 23.6% during the same period [6][28] - The gross margin is expected to stabilize around 18% from 2024 to 2027, while the net margin is projected to rise from 4.5% in 2023 to 9.8% in 2027 [6][28] - The company’s EPS is forecasted to grow from 0.28 yuan in 2023 to 1.31 yuan in 2027, reflecting strong earnings growth [6][28] Business Development - Longxin General has optimized its business structure by focusing on core areas and divesting non-core businesses, which has led to improved profitability [3][28] - The motorcycle segment is expected to see significant growth, with the high-end "Wuji" brand contributing over 30% of motorcycle revenue by 2024, and a compound annual growth rate (CAGR) of 34.9% from 2020 to 2024 [4][52] - The all-terrain vehicle segment is also experiencing rapid growth, with a revenue increase of 73.9% in 2024 [54] - The company is expanding its global presence, with products sold in over 90 countries and more than 2,000 sales points worldwide [4][39] Strategic Changes - The recent change in shareholding structure, with Zongshen New Manufacturing becoming the controlling shareholder, is expected to bring significant synergies and enhance governance [3][22] - The management team remains stable, with experienced leaders who have been with the company for many years, ensuring continuity in strategic execution [25][26]

Investment Rating - The report assigns an "Accumulate" rating to Kelun Pharmaceutical [13] Core Views - The approval of the fourth indication for the subsidiary's core asset SKB264 in China is a positive development, indicating that the sales of innovative drugs are gradually materializing, and there is an expectation for the recovery of the main business [2][13] - The report anticipates total revenue for 2025-2027 to be 174.2 billion, 197.6 billion, and 225.7 billion yuan, respectively, with year-on-year growth rates of -20.1%, 13.4%, and 14.2% [13] - Expected EPS for 2025-2027 is projected to be 0.93, 1.14, and 1.72 yuan [13] - The report highlights that Kelun Pharmaceutical, as a leading company in the industry, has stable business development, and the first product from Kelun Botai is about to be launched overseas, which supports the outlook for the company's innovative drug business [13] Financial Summary - Total revenue for 2023 is projected at 21,454 million yuan, with a year-on-year increase of 12.7% [5] - Net profit attributable to the parent company is expected to be 2,456 million yuan in 2023, reflecting a significant increase of 44.0% [5] - The report provides a detailed financial forecast, including revenue and net profit projections for the next five years, indicating fluctuations in growth rates [5][16] Market Data - The stock price range over the past 52 weeks is between 26.85 and 40.70 yuan, with a total market capitalization of 51,218 million yuan [8] - The report notes that the company has a total equity of 23,708 million yuan and a net asset per share of 14.84 yuan [9] Clinical Development - Kelun Botai has initiated nine registration clinical studies for SKB264 in China, with significant clinical trial results indicating improved progression-free survival (PFS) and overall survival (OS) rates compared to chemotherapy [13]

Investment Rating - The report initiates coverage on Yantai China Pet Foods with an OUTPERFORM rating [1][2]. Core Insights - The company is positioned to capitalize on the global pet economy, leveraging brand and supply chain advantages to unlock incremental growth potential [1][4]. - The pet food market in China is expected to exceed RMB 320 billion by 2025, driven by factors such as the recovery of pet dog numbers post-pandemic and increasing urbanization rates [4]. - The company has established a resilient supply chain through a dual engine of OEM and proprietary brands, enhancing its competitive edge in the global pet food market [8]. Financial Projections - Revenue is projected to grow from RMB 5.36 billion in 2025 to RMB 8.62 billion in 2027, reflecting year-on-year growth rates of 20% and 25% respectively [2][8]. - Net profit is expected to increase from RMB 448 million in 2025 to RMB 748 million in 2027, with a compound annual growth rate of approximately 29% [2][8]. - The diluted EPS is forecasted to rise from RMB 1.52 in 2025 to RMB 2.54 in 2027 [2]. Market Position and Strategy - The company has a significant market share in the pet food industry, with its proprietary brand "Wanpy" expected to contribute over 50% of its self-owned brand revenue by 2024 [29][32]. - The company has expanded its international footprint with 23 factories across various countries, supporting high-margin operations and global brand outreach [6][25]. - The domestic market is increasingly important, with self-owned brand sales growing significantly, reflecting a shift from a historically export-focused model [15][19]. Product Development - The company is focusing on upgrading its product lines, with new high-end offerings under the "Wanpy" brand expected to generate substantial revenue [5][32]. - The introduction of innovative products, such as the "Toptrees" brand, is aimed at capturing the high-end pet food market segment [38]. Sales Channels - The company employs a comprehensive "online + offline" sales strategy, with significant growth in direct sales and a stable customer base [24][25]. - The revenue from direct sales is projected to grow at a compound annual growth rate of 60.3% from 2020 to 2024 [24]. Conclusion - Yantai China Pet Foods is well-positioned to leverage its brand strength and supply chain capabilities to capture growth in the expanding pet food market, with a strong focus on product innovation and market expansion strategies [1][8].

Investment Rating - The report assigns an "Accumulate" rating for the company, marking its first coverage [4]. Core Views - The company, Weilon Co., Ltd., is recognized as a leading supplier of water valves, benefiting from urbanization and industrialization in the Middle East, as well as the rising demand for IDC liquid cooling systems [1][2]. - The company has maintained a steady growth trajectory, with a compound annual growth rate (CAGR) of 10.6% in total revenue from 2017 to 2024, and a CAGR of 11.5% in net profit during the same period [1][24]. - The water treatment valve market is projected to reach approximately 120 billion yuan in 2024, driven by urban construction and industrial infrastructure investments [2][50]. - The company has a significant first-mover advantage in overseas markets, with established production capabilities in Thailand and Saudi Arabia, which will support long-term growth [3][37]. Summary by Sections Company Overview - Weilon Co., Ltd. has been deeply engaged in the water valve industry for over 30 years, with around 75% of its revenue coming from overseas markets, primarily in Europe and North America [1][14]. - The company has successfully expanded its product offerings to include valves for data center infrastructure since 2018, and it became the only qualified supplier of fire valves for Saudi Aramco in Asia by the end of 2021 [1][13]. Market Analysis - The water treatment valve market is the second-largest downstream sector in the industrial valve market, with a stable demand due to ongoing urbanization and infrastructure projects [2][50]. - The Middle East and North Africa are expected to contribute significantly to the water valve market, with an estimated 250 billion USD in water and wastewater treatment projects by the end of 2025 [2][64]. Growth Drivers - The demand for liquid cooling solutions is expected to surge due to the explosion of AI server computing power, with the liquid cooling valve market projected to reach approximately 8.4 billion yuan by 2026 [2][3]. - The company is well-positioned to capitalize on the growth in emerging markets, particularly in the Middle East and North Africa, where urbanization and industrialization are accelerating [2][64]. Financial Projections - The company is projected to achieve net profits of 1.3 billion yuan in 2025, 1.7 billion yuan in 2026, and 2.2 billion yuan in 2027, with corresponding price-to-earnings ratios of 37, 28, and 22 times [4][39]. - The company's gross margin has remained stable at around 40%, with a net profit margin consistently above 20% [28][32].

Investment Rating - The report assigns a "Buy" rating for Longxin General (603766.SH) for the first time [1]. Core Views - Longxin General is a leading company in the motorcycle and all-terrain vehicle sectors in China, with a strategic focus on three main business areas: motorcycles, all-terrain vehicles, and general machinery. The company has made significant advancements in high-end motorcycles and smart garden machinery through continuous product innovation [2][4]. - The collaboration with Zongshen Power, a major shareholder, is expected to enhance the company's core competitiveness through synergies in technology research and development, supply chain management, and overseas channels [2][3]. - The company is projected to achieve net profits of 1.73 billion, 2.25 billion, and 2.70 billion yuan for the years 2025, 2026, and 2027, respectively, with corresponding EPS of 0.84, 1.10, and 1.31 yuan, leading to a PE ratio of 18.9, 14.5, and 12.1 times [2]. Financial Summary - The company's revenue is expected to grow from 13.066 billion yuan in 2023 to 27.396 billion yuan in 2027, with a compound annual growth rate (CAGR) of 15.2% [6]. - The net profit attributable to shareholders is projected to increase from 583 million yuan in 2023 to 2.698 billion yuan in 2027, reflecting a CAGR of 19.7% [6]. - The gross margin is expected to stabilize around 18% from 2024 onwards, while the net margin is projected to rise from 4.5% in 2023 to 9.8% in 2027 [6]. Business Development - Longxin General has optimized its business structure by focusing on core areas and divesting non-core businesses, which has led to improved profitability. The motorcycle and engine business revenue is expected to grow significantly, contributing to 75.4% of total revenue by 2024 [20][28]. - The company has established a comprehensive product matrix covering various motorcycle segments, including high-performance models under the "VOGE" brand, which is expected to drive growth in the mid to high displacement motorcycle market [20][39]. - The all-terrain vehicle (ATV) segment is also experiencing growth, with a revenue increase of 73.9% in 2024, supported by a robust product lineup and expansion into international markets [54][58]. Strategic Changes - The recent change in the company's shareholding structure, with Zongshen New Manufacturing becoming the controlling shareholder, is anticipated to bring significant synergies and enhance governance [3][22]. - The management team remains stable, with experienced leaders who have been with the company for many years, ensuring continuity in strategic execution [25][26]. Market Position - Longxin General has established a global distribution network covering over 90 countries and more than 2,000 sales points, enhancing its brand presence and operational capabilities [4][39]. - The company is well-positioned to capitalize on the growing demand for motorcycles and all-terrain vehicles, particularly in international markets, as it continues to innovate and expand its product offerings [4][39].

Investment Rating - The investment rating for the company is "Buy" [8] Core Insights - The company plans to raise no more than 380 million yuan through a private placement to enhance its product lineup in friction materials and expand into new market scenarios [8] - The strategic focus is on high-growth markets for intelligent driving and new energy vehicles, targeting high-value domestic alternatives in the automotive sector [8] - The company is positioned as the sole domestic supplier of wet paper-based friction plates for passenger vehicles, with significant growth potential in commercial vehicles and engineering machinery [8] Financial Projections - Total revenue is projected to grow from 206.56 million yuan in 2023 to 760.40 million yuan in 2027, reflecting a compound annual growth rate (CAGR) of approximately 34.70% [8] - Net profit attributable to the parent company is expected to increase from 49.18 million yuan in 2023 to 241.84 million yuan in 2027, with a notable growth rate of 38.49% in 2027 [8] - The earnings per share (EPS) is forecasted to rise from 0.87 yuan in 2023 to 4.27 yuan in 2027, indicating a strong upward trend in profitability [8]

Investment Rating - The report maintains a rating of "Buy" for the company [4][8]. Core Insights - The company's consolidated revenue for January 2026 increased by 87.6% year-on-year, with a target price raised to 189.2 CNY, reflecting a 43 times PE ratio for 2026 [4][6]. - The company is expanding its overseas market presence, particularly in Southeast Asia, and has established a wholly-owned subsidiary in Singapore [6][4]. - The financial forecast indicates a projected EPS growth of 5.2%, 40.5%, and 20.2% for 2025, 2026, and 2027 respectively [4][7]. Financial Summary - The consolidated revenue for January 2026 was 6.56 billion NTD (approximately 1.44 billion CNY), with a year-on-year increase of 87.6% and a month-on-month decrease of 30.9% [4]. - The consolidated revenue for Q4 2025 was 25.08 billion NTD (approximately 5.52 billion CNY), showing a year-on-year increase of 133.7% [4]. - The total revenue for 2025 is projected to be 76.74 billion NTD (approximately 16.9 billion CNY), reflecting an 18.1% increase [4][7]. - The company’s net profit for 2026 is forecasted to be 940 million CNY, with a net profit margin of 14.7% [7][4]. Valuation Metrics - The current price is 143.78 CNY, with a target price of 189.20 CNY, indicating significant upside potential [8]. - The company’s PE ratio for 2026 is projected at 31.8 times, while the historical average PE is around 74.2% [6][4]. - The company has a current dividend yield of 1.4%, with a proposed dividend payout ratio of 33.6% for 2024 [6][4].

Investment Rating - The report assigns an "Accumulate" rating to Kelun Pharmaceutical [13] Core Views - The core asset SKB264 of the subsidiary has received approval for its fourth indication in China, indicating a positive outlook for the sales of innovative drugs and an expectation for the recovery of the main business [2][13] - The report anticipates total revenue for 2025-2027 to be 174.2 billion, 197.6 billion, and 225.7 billion yuan, respectively, with year-on-year growth rates of -20.1%, 13.4%, and 14.2% [13] - Expected EPS for 2025-2027 is projected to be 0.93, 1.14, and 1.72 yuan [13] - The report highlights the stable development of various business segments and the upcoming overseas launch of the first product from Kelun Botai, supporting the continued realization of the company's innovative drug business [13] Financial Summary - Total revenue for 2023 is projected at 21,454 million yuan, with a year-on-year growth of 12.7% [5] - Net profit attributable to the parent company is expected to be 2,456 million yuan in 2023, reflecting a significant increase of 44.0% [5] - The report forecasts a net profit margin of 12.3% for 2023, with a projected increase to 14.0% by 2027 [16] - The company’s total assets are estimated to reach 42,588 million yuan by 2027, with a debt-to-equity ratio of 22.9% [16] Market Data - The stock price range over the past 52 weeks is between 26.85 and 40.70 yuan, with a total market capitalization of 51,218 million yuan [8] - The report sets a target price of 45.41 yuan based on a 40x PE ratio for 2026 [13]